Resveratrol counters systemic lupus erythematosus-associated atherogenicity by normalizing cholesterol efflux

Iryna Voloshyna, Isaac Teboul, Michael J. Littlefield, Nicolle M. Siegart, George K. Turi, Melissa J. Fazzari, Steven E. Carsons, Joshua DeLeon, Allison B. Reiss

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Resveratrol is a bioactive molecule used in dietary supplements and herbal medicines and consumed worldwide. Numerous investigations by our group and others have indicated cardioprotective and anti-inflammatory properties of resveratrol. The present study explored potential atheroprotective actions of resveratrol on cholesterol efflux in cultured human macrophages exposed to plasma from systemic lupus erythematosus (SLE) patients. These results were confirmed in ApoE−/−Fas−/− double knockout mice, displaying a lupus profile with accelerated atherosclerosis. Resveratrol treatment attenuated atherosclerosis in these mice. THP-1 human macrophages were exposed to 10% pooled or individual plasma from patients who met diagnostic criteria for SLE. Expression of multiple proteins involved in reverse cholesterol transport (ABCA1, ABCG1, SR-B1, and cytochrome P450 27-hydroxylase) was assessed using QRT-PCR and Western blotting techniques. Ten-week-old ApoE−/−Fas−/− double knockout mice (n = 30) were randomly divided into two equal groups of 15, one of which received 0.01% resveratrol for 10 consecutive weeks. Atherosclerosis progression was evaluated in murine aortas. Bone marrow-derived macrophages (BMDM) were cultured and expression of cholesterol efflux proteins was analyzed in each group of mice. Our data indicate that inhibition of cholesterol efflux by lupus plasma in THP-1 human macrophages is rescued by resveratrol. Similarly, administration of resveratrol in a lupus-like murine model reduces plaque formation in vivo and augments cholesterol efflux in BMDM. This study presents evidence for a beneficial role of resveratrol in atherosclerosis in the specific setting of SLE. Therefore, resveratrol may merit investigation as an additional resource available to reduce lipid deposition and atherosclerosis in humans, especially in such vulnerable populations as lupus patients.

Original languageEnglish (US)
Pages (from-to)1611-1619
Number of pages9
JournalExperimental Biology and Medicine
Volume241
Issue number14
DOIs
StatePublished - Aug 1 2016
Externally publishedYes

Fingerprint

Systemic Lupus Erythematosus
Cholesterol
Macrophages
Atherosclerosis
Apolipoproteins E
Plasmas
Knockout Mice
Bone
Dietary supplements
resveratrol
Herbal Medicine
Vulnerable Populations
Dietary Supplements
Mixed Function Oxygenases
Cytochrome P-450 Enzyme System
Action Potentials
Aorta
Proteins
Anti-Inflammatory Agents
Western Blotting

Keywords

  • atherosclerosis
  • bone marrow-derived macrophages
  • cholesterol transport
  • Systemic lupus erythematosus

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Resveratrol counters systemic lupus erythematosus-associated atherogenicity by normalizing cholesterol efflux. / Voloshyna, Iryna; Teboul, Isaac; Littlefield, Michael J.; Siegart, Nicolle M.; Turi, George K.; Fazzari, Melissa J.; Carsons, Steven E.; DeLeon, Joshua; Reiss, Allison B.

In: Experimental Biology and Medicine, Vol. 241, No. 14, 01.08.2016, p. 1611-1619.

Research output: Contribution to journalArticle

Voloshyna, I, Teboul, I, Littlefield, MJ, Siegart, NM, Turi, GK, Fazzari, MJ, Carsons, SE, DeLeon, J & Reiss, AB 2016, 'Resveratrol counters systemic lupus erythematosus-associated atherogenicity by normalizing cholesterol efflux', Experimental Biology and Medicine, vol. 241, no. 14, pp. 1611-1619. https://doi.org/10.1177/1535370216647181
Voloshyna, Iryna ; Teboul, Isaac ; Littlefield, Michael J. ; Siegart, Nicolle M. ; Turi, George K. ; Fazzari, Melissa J. ; Carsons, Steven E. ; DeLeon, Joshua ; Reiss, Allison B. / Resveratrol counters systemic lupus erythematosus-associated atherogenicity by normalizing cholesterol efflux. In: Experimental Biology and Medicine. 2016 ; Vol. 241, No. 14. pp. 1611-1619.
@article{21be5622e79d477fb15285ad7bafaa39,
title = "Resveratrol counters systemic lupus erythematosus-associated atherogenicity by normalizing cholesterol efflux",
abstract = "Resveratrol is a bioactive molecule used in dietary supplements and herbal medicines and consumed worldwide. Numerous investigations by our group and others have indicated cardioprotective and anti-inflammatory properties of resveratrol. The present study explored potential atheroprotective actions of resveratrol on cholesterol efflux in cultured human macrophages exposed to plasma from systemic lupus erythematosus (SLE) patients. These results were confirmed in ApoE−/−Fas−/− double knockout mice, displaying a lupus profile with accelerated atherosclerosis. Resveratrol treatment attenuated atherosclerosis in these mice. THP-1 human macrophages were exposed to 10{\%} pooled or individual plasma from patients who met diagnostic criteria for SLE. Expression of multiple proteins involved in reverse cholesterol transport (ABCA1, ABCG1, SR-B1, and cytochrome P450 27-hydroxylase) was assessed using QRT-PCR and Western blotting techniques. Ten-week-old ApoE−/−Fas−/− double knockout mice (n = 30) were randomly divided into two equal groups of 15, one of which received 0.01{\%} resveratrol for 10 consecutive weeks. Atherosclerosis progression was evaluated in murine aortas. Bone marrow-derived macrophages (BMDM) were cultured and expression of cholesterol efflux proteins was analyzed in each group of mice. Our data indicate that inhibition of cholesterol efflux by lupus plasma in THP-1 human macrophages is rescued by resveratrol. Similarly, administration of resveratrol in a lupus-like murine model reduces plaque formation in vivo and augments cholesterol efflux in BMDM. This study presents evidence for a beneficial role of resveratrol in atherosclerosis in the specific setting of SLE. Therefore, resveratrol may merit investigation as an additional resource available to reduce lipid deposition and atherosclerosis in humans, especially in such vulnerable populations as lupus patients.",
keywords = "atherosclerosis, bone marrow-derived macrophages, cholesterol transport, Systemic lupus erythematosus",
author = "Iryna Voloshyna and Isaac Teboul and Littlefield, {Michael J.} and Siegart, {Nicolle M.} and Turi, {George K.} and Fazzari, {Melissa J.} and Carsons, {Steven E.} and Joshua DeLeon and Reiss, {Allison B.}",
year = "2016",
month = "8",
day = "1",
doi = "10.1177/1535370216647181",
language = "English (US)",
volume = "241",
pages = "1611--1619",
journal = "Experimental Biology and Medicine",
issn = "1535-3702",
publisher = "SAGE Publications Ltd",
number = "14",

}

TY - JOUR

T1 - Resveratrol counters systemic lupus erythematosus-associated atherogenicity by normalizing cholesterol efflux

AU - Voloshyna, Iryna

AU - Teboul, Isaac

AU - Littlefield, Michael J.

AU - Siegart, Nicolle M.

AU - Turi, George K.

AU - Fazzari, Melissa J.

AU - Carsons, Steven E.

AU - DeLeon, Joshua

AU - Reiss, Allison B.

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Resveratrol is a bioactive molecule used in dietary supplements and herbal medicines and consumed worldwide. Numerous investigations by our group and others have indicated cardioprotective and anti-inflammatory properties of resveratrol. The present study explored potential atheroprotective actions of resveratrol on cholesterol efflux in cultured human macrophages exposed to plasma from systemic lupus erythematosus (SLE) patients. These results were confirmed in ApoE−/−Fas−/− double knockout mice, displaying a lupus profile with accelerated atherosclerosis. Resveratrol treatment attenuated atherosclerosis in these mice. THP-1 human macrophages were exposed to 10% pooled or individual plasma from patients who met diagnostic criteria for SLE. Expression of multiple proteins involved in reverse cholesterol transport (ABCA1, ABCG1, SR-B1, and cytochrome P450 27-hydroxylase) was assessed using QRT-PCR and Western blotting techniques. Ten-week-old ApoE−/−Fas−/− double knockout mice (n = 30) were randomly divided into two equal groups of 15, one of which received 0.01% resveratrol for 10 consecutive weeks. Atherosclerosis progression was evaluated in murine aortas. Bone marrow-derived macrophages (BMDM) were cultured and expression of cholesterol efflux proteins was analyzed in each group of mice. Our data indicate that inhibition of cholesterol efflux by lupus plasma in THP-1 human macrophages is rescued by resveratrol. Similarly, administration of resveratrol in a lupus-like murine model reduces plaque formation in vivo and augments cholesterol efflux in BMDM. This study presents evidence for a beneficial role of resveratrol in atherosclerosis in the specific setting of SLE. Therefore, resveratrol may merit investigation as an additional resource available to reduce lipid deposition and atherosclerosis in humans, especially in such vulnerable populations as lupus patients.

AB - Resveratrol is a bioactive molecule used in dietary supplements and herbal medicines and consumed worldwide. Numerous investigations by our group and others have indicated cardioprotective and anti-inflammatory properties of resveratrol. The present study explored potential atheroprotective actions of resveratrol on cholesterol efflux in cultured human macrophages exposed to plasma from systemic lupus erythematosus (SLE) patients. These results were confirmed in ApoE−/−Fas−/− double knockout mice, displaying a lupus profile with accelerated atherosclerosis. Resveratrol treatment attenuated atherosclerosis in these mice. THP-1 human macrophages were exposed to 10% pooled or individual plasma from patients who met diagnostic criteria for SLE. Expression of multiple proteins involved in reverse cholesterol transport (ABCA1, ABCG1, SR-B1, and cytochrome P450 27-hydroxylase) was assessed using QRT-PCR and Western blotting techniques. Ten-week-old ApoE−/−Fas−/− double knockout mice (n = 30) were randomly divided into two equal groups of 15, one of which received 0.01% resveratrol for 10 consecutive weeks. Atherosclerosis progression was evaluated in murine aortas. Bone marrow-derived macrophages (BMDM) were cultured and expression of cholesterol efflux proteins was analyzed in each group of mice. Our data indicate that inhibition of cholesterol efflux by lupus plasma in THP-1 human macrophages is rescued by resveratrol. Similarly, administration of resveratrol in a lupus-like murine model reduces plaque formation in vivo and augments cholesterol efflux in BMDM. This study presents evidence for a beneficial role of resveratrol in atherosclerosis in the specific setting of SLE. Therefore, resveratrol may merit investigation as an additional resource available to reduce lipid deposition and atherosclerosis in humans, especially in such vulnerable populations as lupus patients.

KW - atherosclerosis

KW - bone marrow-derived macrophages

KW - cholesterol transport

KW - Systemic lupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=84979995276&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979995276&partnerID=8YFLogxK

U2 - 10.1177/1535370216647181

DO - 10.1177/1535370216647181

M3 - Article

C2 - 27190277

AN - SCOPUS:84979995276

VL - 241

SP - 1611

EP - 1619

JO - Experimental Biology and Medicine

JF - Experimental Biology and Medicine

SN - 1535-3702

IS - 14

ER -